Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

NCT02787447 is registered in ClinicalTrials.gov with First People's Hospital of Hangzhou as lead sponsor.

NCT NCT02787447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02787447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
Lead sponsor
First People's Hospital of Hangzhou
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2016
Completion date
May 31, 2020
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung adenocarcinoma